Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612000891820
Ethics application status
Approved
Date submitted
2/08/2012
Date registered
22/08/2012
Date last updated
22/12/2017
Type of registration
Retrospectively registered

Titles & IDs
Public title
Study to determine whether low-dose aspirin in healthy older adults prevents cognitive decline in those identified as having moderate to severe sleep apnoea: the SNORE-ASA substudy of the Aspirin in Reducing Events in the Elderly (ASPREE) study.
Scientific title
Study of Neurocognitive Outcomes, Radiological and retinal effects of Aspirin in Sleep Apnoea to determine the effects of daily low-dose aspirin 100mg versus placebo on cognitive outcomes in the setting of sleep apnoea, in healthy older adults aged 70 and over.
Secondary ID [1] 280959 0
Nil
Universal Trial Number (UTN)
U1111-1133-2126
Trial acronym
SNORE-ASA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cognitive decline 287066 0
Sleep Apnoea 287067 0
Condition category
Condition code
Neurological 287389 287389 0 0
Dementias
Respiratory 287390 287390 0 0
Sleep apnoea

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This study is a sub study of the Aspirin in Reducing Events in the Elderly study (ASPREE, ClinicalTrials.gov identifier NCT01038583, website www.aspree.org). ASPREE is a double blinded, randomised controlled trial of low dose daily aspirin, 100mg oral tablets versus placebo, taken daily for five years in healthy participants aged 70 and over, followed over 5 years for the primary outcomes of dementia-free survival and disability-free survival. It is a primary prevention study.

The SNORE-ASA study will involve a subset of newly enrolling participants in the parent ASPREE study.

Prior to randomisation into the parent ASPREE study, SNORE-ASA participants take home a small, light and portable home sleep apnoea screening device named ApneaLink Plus. This device has a nasal cannula to measure airflow, a finger clip pulse oximeter, and can calculate the Apnoea Hypnoea Index (AHI) and Oxygen Desaturation Index (ODI), both of which are measures of the presence and severity of sleep apnoea. Participants are required to wear this for one night only, at study entry only.

While participants in the ASPREE study are randomised to oral aspirin 100mg or placebo taken once a day for five years, the SNORE-study outcome measures will be performed after 3 years. However, unblinding of whether the SNORE-ASA participants were randomised to either placebo or aspirin will not take place until after the 5 years of the parent ASPREE study.


A further subset of participants in the SNORE-ASA study will undergo a brain MRI and have retinal vascular imaging (also called retinal photography) at baseline and after 3 years to investigate the mechanism by which sleep apnoea may potentiate cognitive decline, and how aspirin may be protective against this.
Intervention code [1] 285398 0
Treatment: Drugs
Intervention code [2] 285407 0
Prevention
Intervention code [3] 285457 0
Early detection / Screening
Comparator / control treatment
placebo - identical in appearance to aspirin, with the same enteric coating.
Control group
Placebo

Outcomes
Primary outcome [1] 287658 0
Cognitive decline as measured by change in the modified mini mental state examination (3MS)
Timepoint [1] 287658 0
3 years
Secondary outcome [1] 298591 0
Change in brain MRI measures of white matter hyperintensity including volume
Timepoint [1] 298591 0
3 years
Secondary outcome [2] 298592 0
Change in Retinal Vascular Imaging (RVI) parameters
Timepoint [2] 298592 0
3 years
Secondary outcome [3] 298607 0
Cognitive decline as defined by a fall in summed average z-scores of >1 SD on any cognitive domain evaluated
Timepoint [3] 298607 0
3 years

Eligibility
Key inclusion criteria
Enrolling into the parent ASPREE study.
Aged 70 and over
Able and willing to provide informed consent
Minimum age
70 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
History of a diagnosed cardiovascular event, including AMI and stroke, atrial fibrillation, serious intercurrent illness likely to cause death within 5 years, cognitive impairment or dementia, disability, anaemia, a current or recurrent condition with a high risk of major bleeding, absolute contraindication or allergy to aspirin.

Also known history of sleep apnoea and/ or current use of continuous positive airways pressure (CPAP) at night

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Enrollment into the parent study ASPREE is through general practitioner co-investigators. Informed consent for participation in ASPREE is obtained by ASPREE research staff. Enrollment into the SNORE-ASA study takes place at the second baseline ASPREE visit, prior to randomisation to either aspirin or placebo in ASPREE.

Randomisation takes place through the parent ASPREE study. All staff remain blinded to treatment allocation through the randomisation procedure.

The randomisation list is generated by an independent statistician using the STATA "ralloc" procedure with randomisation stratified for site and age (<80 yrs and >80 yrs).
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The randomisation list is generated by an independent statistician using the STATA "ralloc" procedure with randomisation stratified for site and age (<80 yrs and >80 yrs).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
27/03/2012
Actual
27/03/2012
Date of last participant enrolment
Anticipated
Actual
6/01/2015
Date of last data collection
Anticipated
29/12/2017
Actual
Sample size
Target
1500
Accrual to date
Final
1400
Recruitment in Australia
Recruitment state(s)
ACT,NSW,SA,VIC
Recruitment postcode(s) [1] 5582 0
3004

Funding & Sponsors
Funding source category [1] 285748 0
Government body
Name [1] 285748 0
NHMRC
Country [1] 285748 0
Australia
Primary sponsor type
University
Name
Monash University
Address
ASPREE National Co-ordinating Centre
Department of Epidemiology and Preventive Medicine
Ground Floor, Burnet Building
89 Commercial Rd
Melbourne VIC 3004
Country
Australia
Secondary sponsor category [1] 284609 0
None
Name [1] 284609 0
Address [1] 284609 0
Country [1] 284609 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 287754 0
The Alfred Health Human Ethics Committee
Ethics committee address [1] 287754 0
Ethics committee country [1] 287754 0
Australia
Date submitted for ethics approval [1] 287754 0
21/11/2011
Approval date [1] 287754 0
30/01/2012
Ethics approval number [1] 287754 0
1/11/0452
Ethics committee name [2] 287755 0
Monash University Human Research Ethics Committee
Ethics committee address [2] 287755 0
Ethics committee country [2] 287755 0
Australia
Date submitted for ethics approval [2] 287755 0
01/02/2012
Approval date [2] 287755 0
13/02/2012
Ethics approval number [2] 287755 0
CF12/0367
Ethics committee name [3] 296429 0
ACT Health Human Research Ethics Committee
Ethics committee address [3] 296429 0
Ethics committee country [3] 296429 0
Australia
Date submitted for ethics approval [3] 296429 0
05/11/2012
Approval date [3] 296429 0
30/11/2012
Ethics approval number [3] 296429 0
10.12.245
Ethics committee name [4] 296430 0
University of Adelaide Human Research Ethics Committee
Ethics committee address [4] 296430 0
Ethics committee country [4] 296430 0
Australia
Date submitted for ethics approval [4] 296430 0
01/11/2012
Approval date [4] 296430 0
13/12/2012
Ethics approval number [4] 296430 0
H-2012-162

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 34526 0
Prof Elsdon Storey
Address 34526 0
Department of Neuroscience
Alfred Hospital
Commercial Road
Melbourne, VIC
3004
Australia
Country 34526 0
Australia
Phone 34526 0
+61 3 90762552
Fax 34526 0
Email 34526 0
[email protected]
Contact person for public queries
Name 17773 0
Dr Stephanie Ward
Address 17773 0
ASPREE National Coordinating Centre
Ground Floor, Burnet Building
89 Commercial Rd
Melbourne 3004
Victoria
Country 17773 0
Australia
Phone 17773 0
1800 728 745
Fax 17773 0
+61 03 9903 0979
Email 17773 0
[email protected]
Contact person for scientific queries
Name 8701 0
Dr Stephanie Ward
Address 8701 0
ASPREE National Coordinating Centre
Ground Floor, Burnet Building
89 Commercial Rd
Melbourne 3004
Victoria
Country 8701 0
Australia
Phone 8701 0
1800 728 745
Fax 8701 0
+61 03 9903 0979
Email 8701 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseAge-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD study.2017https://dx.doi.org/10.1016/j.conctc.2017.03.005
N.B. These documents automatically identified may not have been verified by the study sponsor.